Biotechnology News and Research

RSS

FDA assigns BYDUREON new PDUFA action date of October 22, 2010

Amylin Pharmaceuticals, Inc., Eli Lilly and Company and Alkermes, Inc. today announced that the U.S. Food and Drug Administration (FDA) has classified the BYDUREON™ (exenatide for extended-release injectable suspension) complete response as a Class 2 resubmission and assigned a new Prescription Drug User Fee Act (PDUFA) action date of October 22, 2010.

6 May 2010

Momenta Pharmaceuticals first-quarter net loss decreases to $16.1 million

Momenta Pharmaceuticals, Inc., a biotechnology company specializing in the characterization and engineering of complex drugs, today reported its financial results for the quarter ended March 31, 2010.

6 May 2010

Aeterna Zentaris granted FDA orphan-drug designation for AEZS-108 in ovarian cancer

Aeterna Zentaris Inc. a late-stage drug development company specialized in oncology and endocrinology, today announced that it has received from the U.S. Food and Drug Administration (FDA), orphan-drug designation for AEZS-108, its doxorubicin targeted conjugate compound, for the treatment of ovarian cancer. AEZS-108 is currently in a Phase 2 trial in advanced ovarian and advanced endometrial cancer in Europe.

6 May 2010

ArQule reports net loss of $9,752,000 for first-quarter 2010

ArQule, Inc. today announced its financial results for the first quarter of 2010.

6 May 2010

Neuroscientists investigate alcohol dependency, withdrawal in C. elegans worms

Drinking alcohol over a long period of time profoundly affects the brain, which adapts to the intoxicant and causes withdrawal symptoms when consumption stops.

6 May 2010

Vical reports net loss of $8.5 million for first-quarter 2010

Vical Incorporated today reported financial results for the quarter ended March 31, 2010. Revenues were $1.5 million for the first quarter of 2010 compared with $2.3 million for the first quarter of 2009, reflecting lower revenues under the company's license agreement with AnGes MG, Inc. Operating expenses were $10.1 million for the first quarter of 2010 compared with $10.6 million for the first quarter of 2009.

6 May 2010

ViaCyte granted three new U.S. patents

ViaCyte, Inc., a preclinical stage stem cell engineering company focused on diabetes, announced today that it has received three additional U.S. Patents.

6 May 2010

Southeast Pain Care offers non-addictive alternatives to pain relief

The untimely death of Michael Jackson has brought the issue of pain medication addiction to the forefront of American media recently. The good news for people suffering with pain is that there are several non-addictive alternatives to pain relief.

6 May 2010

Intercell to acquire Cytos' platform technology for monoclonal antibody discovery

Intercell AG today announced that it has signed an agreement with Cytos Biotechnology Ltd. to acquire Cytos' platform technology for monoclonal antibody discovery. The technology is based on expression cloning of monoclonal antibodies from human B-cells and enables the identification of anti-infective antibodies to prevent and treat infectious diseases.

6 May 2010

ThromboGenics, BioInvent International report positive results from Phase II trial of TB-402 for VTE

ThromboGenics NV and co-development partner BioInvent International announce today positive results from their Phase II trial of TB-402. TB-402 is a novel, long acting anticoagulant that is being developed as a single injection for the prevention of venous thromboembolism (VTE) following orthopaedic surgery.

6 May 2010

Positive results from Phase 2 clinical study of LX1031 in IBS patients presented at DDW 2010

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering and developing breakthrough treatments for human disease, presented results from its positive Phase 2 clinical study with LX1031 in patients with non-constipating irritable bowel syndrome at Digestive Disease Week 2010 in New Orleans, Louisiana.

6 May 2010

Genomic Health reports 22% revenue growth, 58% decrease in net loss for first-quarter 2010

Genomic Health, Inc. today reported financial results and business progress for the quarter ended March 31, 2010.

6 May 2010

Alnylam Pharmaceuticals reports consolidated financial results for first quarter 2010

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, today reported its consolidated financial results for the first quarter ended March 31, 2010, and company highlights.

6 May 2010

Innate Therapeutics receives funding to conduct Phase 2A clinical trial for MIS416

Innate Therapeutics today announced funding support from Fast Forward, LLC, a not-for-profit organization established by the U.S. National Multiple Sclerosis Society and EMD Serono, an affiliate of Merck KGaA, Darmstadt, Germany. The award of funds will help support the conduct of a Phase 2A clinical trial in patients with progressive forms of MS using MIS416, a naturally occurring agent derived from bacteria.

6 May 2010

Endo Pharmaceuticals to acquire all outstanding shares of HealthTronics common stock

HealthTronics, Inc., a leading provider of urological products and services, today announced that it has signed a definitive merger agreement with Endo Pharmaceuticals pursuant to which Endo will acquire HealthTronics.

6 May 2010

Novocell is now ViaCyte

Novocell, Inc., a preclinical stage stem cell engineering company focused on diabetes, announced today the Company's shareholders and Board of Directors approved a name change to ViaCyte, Inc.

6 May 2010

GeoVax Labs reports net loss of $690,789 for first-quarter 2010

GeoVax Labs, Inc., a biotechnology company that creates, develops and tests innovative HIV/AIDS vaccines, today announced its financial results for the three months ended March 31, 2010.

6 May 2010

Endo Pharmaceuticals signs agreement to acquire HealthTronics

Continuing to diversify, move into new growth areas beyond pharmaceuticals, and strengthen its commitment to improved patient outcomes in urology, Endo Pharmaceuticals today announced that it has signed an agreement to acquire HealthTronics, Inc., a leading U.S. provider of urological products and services.

6 May 2010

Vaccinogen chooses Clinipace Worldwide to manage pivotal phase 3b confirmatory trial for OncoVAX

Clinipace Worldwide, a global full-service clinical research organization (CRO), announced today that Vaccinogen, a biotechnology company with more than three decades experience researching how to combat cancer using the body's own immune system, has selected the company to manage a pivotal phase 3b confirmatory trial for OncoVAX in the treatment of Stage II Colon Cancer.

6 May 2010

United BioSource Corporation acquires Abt Bio-Pharma Solutions

Abt Associates announced today the sale of its wholly-owned subsidiary Abt Bio-Pharma Solutions, Inc. to United BioSource Corporation, a global scientific and medical affairs organization that partners with life science companies to develop and commercialize biopharmaceuticals, medical devices, and other health care technologies.

6 May 2010

Biotechnology News and Research

FDA assigns BYDUREON new PDUFA action date of October 22, 2010

Momenta Pharmaceuticals first-quarter net loss decreases to $16.1 million

Aeterna Zentaris granted FDA orphan-drug designation for AEZS-108 in ovarian cancer

ArQule reports net loss of $9,752,000 for first-quarter 2010

Neuroscientists investigate alcohol dependency, withdrawal in C. elegans worms

Vical reports net loss of $8.5 million for first-quarter 2010

ViaCyte granted three new U.S. patents

Southeast Pain Care offers non-addictive alternatives to pain relief

Intercell to acquire Cytos' platform technology for monoclonal antibody discovery

ThromboGenics, BioInvent International report positive results from Phase II trial of TB-402 for VTE

Positive results from Phase 2 clinical study of LX1031 in IBS patients presented at DDW 2010

Genomic Health reports 22% revenue growth, 58% decrease in net loss for first-quarter 2010

Alnylam Pharmaceuticals reports consolidated financial results for first quarter 2010

Innate Therapeutics receives funding to conduct Phase 2A clinical trial for MIS416

Endo Pharmaceuticals to acquire all outstanding shares of HealthTronics common stock

Novocell is now ViaCyte

GeoVax Labs reports net loss of $690,789 for first-quarter 2010

Endo Pharmaceuticals signs agreement to acquire HealthTronics

Vaccinogen chooses Clinipace Worldwide to manage pivotal phase 3b confirmatory trial for OncoVAX

United BioSource Corporation acquires Abt Bio-Pharma Solutions

Industry Focus eBook - Biotechnology (4th edition) eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News